If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 31 - 40 of 278
A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination with Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma a
Objective
ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer
Protocol No
ASTELLAS-2138-CL-0101
Categories
A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
Objective
Phase 1-2 DISC-0974 in Myelofibrosis and Anemia
Protocol No
DISC-0974-102
Categories
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Objective
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
Protocol No
AZ-D933GC00002-EMERALD-Y90
Categories
A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin Versus No HIPEC At the Time of Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian
Objective
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal & FT
Protocol No
GOG-3068-HOTT-HIPEC
Categories
A Phase 3, Open-Label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Objective
Study comparing tarlatamab and durvalumab versus durvalumab alone in first-line ES-SCLC
Protocol No
AMG-757-20200041-DELLPHI-305
Categories
A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)
Objective
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
Protocol No
ECOG-EA6192
Categories
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Objective
Study of loncastuximab tesirine in R/R B-cell Non-Hodgkin lymphoma patients
Protocol No
ADCT-402-105-LOTIS-7
Categories
Concept Identification for MEG Aphasia
Objective
Concept Identification for MEG Aphasia
Protocol No
ANES-IIT-GROSS-CONCEPT-ID
Categories
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
Objective
A Phase 1b/2 Study of BGB-11417 in Patients with Myeloid Malignancies
Protocol No
BEIGENE-BGB-11417-103
Categories
Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants
Objective
Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants
Protocol No
CVC-ABBOTT-CATALYST
Categories